Galectin-3 Research

2021 Translational Study: Galectin-3 in septic acute kidney injury: a translational study

2021 Preclinical Study: Galectin-3 participates in PASMC migration and proliferation by interacting with TGF-β1

2021 Translational Study: A translational study of Galectin-3 as an early biomarker and potential therapeutic target for ischemic-reperfusion induced acute kidney injury

2020 Preclinical Study: Galectin-3 Inhibition Reduces Diabetes-Associated Cognitive Impairment, Oxidative Stress and Neuroinflammationopens PDF file

2020 Review: Hyperinflammation and Fibrosis in Severe COVID-19 Patients: Galectin-3, a Target Molecule to Consider

2020 Review: A Potential Role for Galectin-3 Inhibitors in the Treatment of COVID-19

2020 Prospective Cohort Study: Gal-3 a Potential Biomarker of Vascular Calcification for Maintenance Hemodialysis (MHD) Patients

2020 Clinical Study: Galectin-3 a Biomarker for the Early Detection of Diabetic Kidney Disease (DKD)

2020 Review and Meta-analysis: Serum Galectin-3 is Associated with Increased Risk of Atrial Fibrillation Recurrence

2020 Preclinical Study: Gal-3 Signaling Pathway is Related to Pathogenesis of Atrial Fibrillation in Diabetes

opens in a new window2019 Preclinical Study: Galectin-3 Blocker Targets Galectin-3-Induced STAT3 Activation to Synergize with Chemotherapy Drug Paclitaxel Against Ovarian Cancer

opens in a new window2019 Preclinical Study: Galectin-3 Inhibition Improves Ischemic Heart Failure by Downregulating Galectin 3 and Reducing Myocardial Fibrosis

opens in a new window2019 Preclinical Study: Blockade of Galectin-3 Prevents Profibrotic and Proinflammatory Effects of Cardiotrophin-1 (CT-1) in Myocardial Fibrosis

opens in a new window2019 Preclinical Study: Blockade of Galectin-3 Prevents Cardiac Damage, Inflammation, and Fibrosis Following Kidney Injury

opens in a new window2019 Preclinical Study: Galectin-3 Inhibitor Reduces the Pro-Inflammatory, Pro-fibrotic, and Pro-osteogenic Response in Aortic valves in Patients Undergoing Aortic Valve Replacement

opens in a new window2019 Preclinical Study: Blockade of Galectin-3 Prevents Cardiac Fibrosis, Inflammation and Functional Alterations

2018 Clinical Study: Thoughts Modulate Expression of Inflammatory Genes

opens in a new window2018 Preclinical Study: Modified Citrus Pectin Prevents Blood-Brain Barrier Disruption in Mouse Subarachnoid Hemorrhage by Inhibiting Galectin-3

opens in a new window2018 Preclinical Study: Blockade of Galectin-3 Protects Against Renal Injury and Fibrosis

2018 Preclinical Study: Inhibition of Galectin-3 Mitigates Diet-Induced Cardiac Lipotoxicity and Reduces Mitochondrial Damage

opens in a new window2018 Preclinical Study: Inhibition of Galectin-3 Reduces Inflammatory Mediators and Decreases Kidney Damage in Spontaneous Hypertension Model

2017 Review: Galectin-3—A Key Player in Arthritis

2017 Preclinical Study: Galectin-3 Blockade Protects Vascular Tissue against Abdominal Aortic Aneurism

opens in a new window2017 Preclinical Study: Galectin-3 Blockade Prevents Cardiac Remodeling, Fibrosis and Inflammation Associated with Early Aortic Stenosis

opens in a new window2017 Preclinical Study: Galectin-3 Inhibition Reduces Size of Atherosclerotic Lesions

opens in a new window2017 Preclinical Study: Galectin-3 inhibition Blocks Inflammation, Fibrosis and Calcification in Aortic Valves

opens in a new window2016 Preclinical Study: Galectin-3 Blockade Reduces Renal Fibrosis, Inflammation and Damage

opens in a new window2016 Preclinical Study: Inhibition of Galectin-3 Prevents Adipose Tissue Remodeling in Obesity

opens in a new window2016 Preclinical Study: Galectin-3 Blockade Suppresses Neuropathic Pain and Decreases Proinflammatory Mediators Following Peripheral Nerve Injury

opens in a new window2015 Preclinical Study: Inhibition of Galectin-3 Prevents Obesity-Related Cardiovascular Remodeling

opens in a new window2013 Preclinical Study: Galectin-3 Blockade Reverses Vascular Hypertrophy and Fibrosis

opens in a new window2013 Preclinical Study: Modified Citrus Pectin Reverses Vascular Hypertrophy and Fibrosis, via Inhibition of Galectin-3

opens in a new window2012 American Heart Association Study: Galectin-3 Mediates Aldosterone-Induced Vascular Fibrosis

opens in a new window2012 Review: Circulating Galectin-3 in the Bloodstream: An Emerging Promoter of Cancer Metastasis

opens in a new window2011 Preclinical Study: Galectin 3 Aggravates Joint Inflammation and Destruction in Antigen-Induced Arthritis.

opens in a new window2011 Preclinical Study: Galectin-3 Blockade Reduces Kidney Disease Severity

Additional Galectin-3 Research Areas

opens in a new windowRead More:  Galectin-3 in Arthritis & Inflammation

opens in a new windowRead More: Galectin-3 in Bladder Cancer

opens in a new windowRead More: Galectin-3 in Breast Cancer

opens in a new windowRead More:  Galectin-3 in Prostate Cancer

opens in a new windowRead More: Galectin-3 in Cancer Metastasis

opens in a new windowRead More:  Cardiovascular/Circulatory System

opens in a new windowRead More:  Galectin Structural/Binding/Function

opens in a new windowRead More:  Galectin-3 and Gastrointestinal

opens in a new windowRead More: Galectin-3 in Immunity & Autoimmunity

opens in a new windowRead More:  Galectin-3 in Kidney

opens in a new windowRead More:  Galectin-3 in Liver

opens in a new windowRead More:  Galectin-3 in Lungs

opens in a new windowRead More:  Galectin-3 Parasites

opens in a new windowRead More: Galectin-3 in Diabetes

opens in a new windowRead More:  Galectin-3 in Skin

Accessibility Tools
hide